Cigna Files 8-K for Administrative Update, No New Financials

TL;DR

**Cigna's 8-K is a routine administrative update, nothing new for traders.**

AI Summary

The Cigna Group filed an 8-K on January 31, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing primarily serves to update administrative details, including its incorporation in Delaware and its main business address at 900 Cottage Grove Road, Bloomfield, Connecticut. For investors, this filing is largely procedural and doesn't contain new financial or operational news, meaning it has minimal direct impact on the stock's immediate valuation or outlook.

Why It Matters

This filing is largely administrative, confirming Cigna's corporate details and stock exchange listing, and does not contain new financial or operational information that would typically move the stock.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or legal risks to the company.

Analyst Insight

Smart investors would note this as a routine administrative filing and not expect any immediate stock price movement or significant new information from it. Focus should remain on future earnings reports or material event filings.

Key Players & Entities

• The Cigna Group (company) — registrant of the 8-K filing
• Delaware (company) — state of incorporation for The Cigna Group
• New York Stock Exchange, Inc. (company) — exchange where Cigna's Common Stock is registered
• CI (company) — trading symbol for Cigna's Common Stock
• 900 Cottage Grove Road, Bloomfield, Connecticut 06002 (company) — principal executive offices address

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. I
• $3.7 billion — otal transaction value of approximately $3.7 billion. In connection with the transaction, Ci
• $1.5 billion — recognize an estimated pre-tax loss of $1.5 billion in net income as of December 31, 2023,

Filing Documents

• cigna8k.htm (8-K) — 29KB
• ex99-1.htm (EX-99.1) — 21KB
• image_001.jpg (GRAPHIC) — 2KB
• 0000950159-24-000025.txt ( ) — 235KB
• ci-20240131.xsd (EX-101.SCH) — 3KB
• ci-20240131_lab.xml (EX-101.LAB) — 34KB
• ci-20240131_pre.xml (EX-101.PRE) — 22KB
• cigna8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On January 31, 2024, The Cigna Group ("Cigna") issued a press release announcing the entry into a share purchase agreement with Health Care Service Corporation ("HCSC") pursuant to which, among other things, Cigna will sell to HCSC Cigna's Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D and CareAllies businesses for a total transaction value of approximately $3.7 billion. In connection with the transaction, Cigna will recognize an estimated pre-tax loss of $1.5 billion in net income as of December 31, 2023, which primarily represents asset write offs and costs to sell. The loss on sale will not affect adjusted income from operations or adjusted income from operations per share for the fourth quarter of 2023. Subject to applicable regulatory approvals and other customary closing conditions, Cigna expects to complete this transaction in the first quarter of 2025. A copy of the press release is attached as Exhibit 99.1 to this report and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release, issued January 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL). Forward-Looking CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K (the "Report"), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, Group's long-term annual adjusted income from operations, per share, growth target; statements regarding The Cigna Group's capital deployment priorities and share repurchase plans; statements relating to the impact of the sale of The Cigna Group's Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D and CareAllies businesses, including, without limitation, the ultimate transaction value, the projected impact of the transaction on The Cigna Group's adjusted income from operations, per share, the expected closing date for the transaction, the expected use of proceeds and the projected impact of the transaction on the parties; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-

Forward-looking statements are subject to risks and uncertainties, both

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: the ability to obtain the regulatory approvals necessary for the transaction, on the anticipated timing or at all; the ability to satisfy the closing conditions for the transaction, on the anticipated timing or at all; changes in the anticipated timing for closing the transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement; effects on the business as a result of uncertainty surrounding the proposed transaction; diversion of management time from ongoing business operations due to the transaction; the risk of any unexpected costs or expenses resulting from the transaction; the risk of litigation and/or regulatory actions related to the transaction; our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our abil

View Full Filing

View this 8-K filing on SEC EDGAR